Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Li, Tiejun ^b   Cheng, Hao ^a   Yuan, Hong ^a   Xu, Qiming ^a   Shu, Chang ^c   Zhang, Yuefan ^b   Xu, Pengbiao ^a   Tan, Jason ^c   Rui, Yaocheng ^b   Li, Pingwei ^c   Tan, Xiangshi ^a  

^a FUDAN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIC GUANOSINE MONOPHOSPHATE-ADENOSINE MONOPHOSPHATE; CYCLIC NUCLEOTIDE; CYTOKINE; FLUOROURACIL; INTERFERON REGULATORY FACTOR 3; IRF3 PROTEIN, MOUSE; MB21D1 PROTEIN, MOUSE; MEMBRANE PROTEIN; MPYS PROTEIN, MOUSE; NUCLEOTIDYLTRANSFERASE;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; DENDRITIC CELL; DRUG EFFECTS; INNATE IMMUNITY; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CYTOKINES; DENDRITIC CELLS; FLUOROURACIL; IMMUNITY, INNATE; INTERFERON REGULATORY FACTOR-3; MEMBRANE PROTEINS; MICE, INBRED BALB C; NUCLEOTIDES, CYCLIC; NUCLEOTIDYLTRANSFERASES;

EID: 84954405682     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19049     Document Type: Article

References (66)

1. Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1-10, doi: 10.1016/j. immuni.2013.07.012 (2013).
2. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews. Cancer 12, 252-264, doi: 10.1038/nrc3239 (2012).
3. Couzin-Frankel, J. Immune therapy steps up the attack. Science 330, 440-443, doi: 10.1126/science.330.6003.440 (2010).
4. Dhodapkar, M. V., Dhodapkar, K. M. & Palucka, A. K. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance. Cell death and differentiation 15, 39-50, doi: 10.1038/sj.cdd.4402247 (2008).
5. Waldmann, T. A. Immunotherapy: past, present and future. Nature medicine 9, 269-277, doi: 10.1038/nm0303-269 (2003).
6. Engelhardt, J. J. et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer cell 21, 402-417, doi: 10.1016/j.ccr.2012.01.008 (2012).
7. Palucka, K. & Banchereau, J. Cancer immunotherapy via dendritic cells. Nature reviews. Cancer 12, 265-277, doi: 10.1038/nrc3258 (2012).
8. Schiavoni, G., Mattei, F. & Gabriele, L. Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response. Front Immunol 4, 483, doi: 10.3389/fimmu.2013.00483 (2013).
9. Sun, L., Wu, J., Du, F., Chen, X. & Chen, Z. J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339, 786-791, doi: 10.1126/science.1232458 (2013).
10. Gao, P. et al. Cyclic [G(2′, 5′)pA(3′, 5′)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell 153, 1094-1107, doi: 10.1016/j.cell.2013.04.046 (2013).
11. Ablasser, A. et al. cGAS produces a 2′ -5′ -linked cyclic dinucleotide second messenger that activates STING. Nature 498, 380-384, doi: 10.1038/nature12306 (2013).
12. Diner, E. J. et al. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell reports 3, 1355-1361, doi: 10.1016/j.celrep.2013.05.009 (2013).
13. Zhang, X. et al. Cyclic GMP-AMP containing mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. Mol Cell 51, 226-235, doi: 10.1016/j.molcel.2013.05.022 (2013).
14. Cai, X., Chiu, Y. H. & Chen, Z. J. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Molecular cell 54, 289-296, doi: 10.1016/j.molcel.2014.03.040 (2014).
15. Tanaka, Y. & Chen, Z. J. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Science signaling 5, ra20, doi: 10.1126/scisignal.2002521 (2012).
16. Stetson, D. B. & Medzhitov, R. Type I interferons in host defense. Immunity 25, 373-381, doi: 10.1016/j.immuni.2006.08.007 (2006).
17. Schneider, W. M., Chevillotte, M. D. & Rice, C. M. Interferon-stimulated genes: a complex web of host defenses. Annual review of immunology 32, 513-545, doi: 10.1146/annurev-immunol-032713-120231 (2014).
18. Woo, S. R. et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41, 830-842, doi: 10.1016/j.immuni.2014.10.017 (2014).
19. Deng, L. et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Immunity 41, 843-852, doi: 10.1016/j.immuni.2014.10.019 (2014).
20. Yang, X., Du, J., Xu, X., Xu, C. & Song, W. IFN-gamma-secreting-mesenchymal stem cells exert an antitumor effect in vivo via the TRAIL pathway. J Immunol Res 2014, 318098, doi: 10.1155/2014/318098 (2014).
21. Li, X. et al. Cyclic GMP-AMP synthase is activated by double-stranded DNA-induced oligomerization. Immunity 39, 1019-1031, doi: 10.1016/j.immuni.2013.10.019 (2013).
22. Shu, C., Yi, G., Watts, T., Kao, C. C. & Li, P. Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune system. Nat Struct Mol Biol 19, 722-724, doi: 10.1038/nsmb.2331 (2012).
23. Civril, F. et al. Structural mechanism of cytosolic DNA sensing by cGAS. Nature 498, 332-337, doi: 10.1038/nature12305 (2013).
24. Kranzusch, P. J., Lee, A. S., Berger, J. M. & Doudna, J. A. Structure of human cGAS reveals a conserved family of second-messenger enzymes in innate immunity. Cell reports 3, 1362-1368, doi: 10.1016/j.celrep.2013.05.008 (2013).
25. Zhang, X. et al. The cytosolic DNA sensor cGAS forms an oligomeric complex with DNA and undergoes switch-like conformational changes in the activation loop. Cell reports 6, 421-430, doi: 10.1016/j.celrep.2014.01.003 (2014).
26. Gao, P. et al. Structure-function analysis of STING activation by c[G(2′, 5′)pA(3′, 5′)p] and targeting by antiviral DMXAA. Cell 154, 748-762, doi: 10.1016/j.cell.2013.07.023 (2013).
27. Li, X. D. et al. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science 341, 1390-1394, doi: 10.1126/science.1244040 (2013).
28. Bridgeman, A. et al. Viruses transfer the antiviral second messenger cGAMP between cells. Science 349, 1228-1232, doi: 10.1126/science.aab3632 (2015).
29. Gentili, M. et al. Transmission of innate immune signaling by packaging of cGAMP in viral particles. Science 349, 1232-1236, doi: 10.1126/science.aab3628 (2015).
30. Gao, D. et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. Science 341, 903-906, doi: 10.1126/science.1240933 (2013).
31. Diamond, M. S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208, 1989-2003, doi: 10.1084/jem.20101158 (2011).
32. Gajewski, T. F. & Corrales, L. New perspectives on type I IFNs in cancer. Cytokine & growth factor reviews 26, 175-178, doi: 10.1016/j.cytogfr.2015.01.001 (2015).
33. Yang, X. et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 25, 37-48, doi: 10.1016/j.ccr.2013.12.004 (2014).
34. Joffre, O. P., Segura, E., Savina, A. & Amigorena, S. Cross-presentation by dendritic cells. Nature reviews. Immunology 12, 557-569, doi: 10.1038/nri3254 (2012).
35. Barreira da Silva, R. & Munz, C. Natural killer cell activation by dendritic cells: balancing inhibitory and activating signals. Cellular and molecular life sciences : CMLS 68, 3505-3518, doi: 10.1007/s00018-011-0801-8 (2011).
36. Skrnjug, I., Guzman, C. A. & Rueckert, C. Cyclic GMP-AMP displays mucosal adjuvant activity in mice. PloS one 9, e110150, doi: 10.1371/journal.pone.0110150 (2014).
37. Bronte, V. Tumors STING adaptive antitumor immunity. Immunity 41, 679-681, doi: 10.1016/j.immuni.2014.11.004 (2014).
38. Montoya, M. et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99, 3263-3271 (2002).
39. Carey, M. P. & Burish, T. G. Etiology and treatment of the psychological side effects associated with cancer chemotherapy: a critical review and discussion. Psychological bulletin 104, 307-325 (1988).
40. Kennedy, B. J. 5-fluorouracil toxicity: old or new? Cancer 86, 1099-1100 (1999).
41. Fata, F. et al. 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 86, 1129-1134 (1999).
42. Liu, X. et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med, doi: 10.1038/nm.3931 (2015).
43. Hansen, M., Met, O., Svane, I. M. & Andersen, M. H. Cellular based cancer vaccines: type 1 polarization of dendritic cells. Current medicinal chemistry 19, 4239-4246 (2012).
44. Farkas, A. & Kemeny, L. Interferon-alpha in the generation of monocyte-derived dendritic cells: recent advances and implications for dermatology. Br J Dermatol 165, 247-254, doi: 10.1111/j.1365-2133.2011.10301.x (2011).
45. Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nature medicine 5, 1249-1255, doi: 10.1038/15200 (1999).
46. Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nature reviews. Immunology 6, 836-848, doi: 10.1038/nri1961 (2006).
47. Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nature immunology 14, 1014-1022, doi: 10.1038/ni.2703 (2013).
48. Fuertes, M. B., Woo, S. R., Burnett, B., Fu, Y. X. & Gajewski, T. F. Type I interferon response and innate immune sensing of cancer. Trends in immunology 34, 67-73, doi: 10.1016/j.it.2012.10.004 (2013).
49. Temizoz, B. et al. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. European journal of immunology 45, 1159-1169, doi: 10.1002/eji.201445132 (2015).
50. Ikeda, H., Old, L. J. & Schreiber, R. D. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine & growth factor reviews 13, 95-109 (2002).
51. Boehm, U., Klamp, T., Groot, M. & Howard, J. C. Cellular responses to interferon-gamma. Annual review of immunology 15, 749-795, doi: 10.1146/annurev.immunol.15.1.749 (1997).
52. Blankenstein, T. & Qin, Z. The role of IFN-gamma in tumor transplantation immunity and inhibition of chemical carcinogenesis. Current opinion in immunology 15, 148-154 (2003).
53. Ishihara, K. & Hirano, T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine & growth factor reviews 13, 357-368 (2002).
54. Fisher, D. T., Appenheimer, M. M. & Evans, S. S. The two faces of IL-6 in the tumor microenvironment. Seminars in immunology 26, 38-47, doi: 10.1016/j.smim.2014.01.008 (2014).
55. Parihar, R., Dierksheide, J., Hu, Y. & Carson, W. E. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. The Journal of clinical investigation 110, 983-992, doi: 10.1172/JCI15950 (2002).
56. Dias, S., Boyd, R. & Balkwill, F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. International journal of cancer. Journal international du cancer 78, 361-365, doi: 10.1002/(SICI)1097-0215(19981029)78:3<361::AID-IJC17>3.0.CO;2-9 (1998).
57. Riemensberger, J., Bohle, A. & Brandau, S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clinical and experimental immunology 127, 20-26 (2002).
58. Salcedo, R. et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96, 34-40 (2000).
59. Saji, H. et al. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92, 1085-1091 (2001).
60. Yang, A. S. & Lattime, E. C. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer research 63, 2150-2157 (2003).
61. Wallace, A. et al. The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes. Cancer Res 67, 7011-7019, doi: 10.1158/0008-5472.can-06-3757 (2007).
62. Zhao, L., Ching, L. M., Kestell, P., Kelland, L. R. & Baguley, B. C. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int J Cancer 116, 322-326, doi: 10.1002/ijc.21005 (2005).
63. Conlon, J. et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol 190, 5216-5225, doi: 10.4049/jimmunol.1300097 (2013).
64. Tadagavadi, R. K., Gao, G., Wang, W. W., Gonzalez, M. R. & Reeves, W. B. Dendritic Cell Protection from Cisplatin Nephrotoxicity Is Independent of Neutrophils. Toxins (Basel) 7, 3245-3256, doi: 10.3390/toxins7083245 (2015).
65. Tadagavadi, R. K. & Reeves, W. B. Renal dendritic cells ameliorate nephrotoxic acute kidney injury. J Am Soc Nephrol 21, 53-63, doi: 10.1681/ASN.2009040407 (2010).
66. Inaba, K. et al. Isolation of dendritic cells. Curr Protoc Immunol Chapter 3, Unit 3 7, doi: 10.1002/0471142735.im0307s86 (2009).